Compare Rivian Automotive, Inc. (RIVN) vs Summit Therapeutics Inc (SMMT) Price & Performance

Rivian Automotive (RIVN) trades at $16.17, up 2.73% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $18.70. The company continues to report significant net losses but has shown improvement in revenue growth and gross profit margins, while recent news highlights strong demand for the R2 SUV and advancements in autonomy capabilities.

The outlook for RIVN hinges on successful R2 production scaling and path to profitability, with upside potential from current levels but high execution risk amid competitive EV market pressures and persistent cash burn requiring ongoing financing.

Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.

The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.